LAUSANNE, Switzerland & SAN FRANCISCO– Amazentis, an innovative Swiss life sciences company pioneering scientific breakthroughs in nutrition, announced today the initiation of a randomized, double-blinded, placebo-controlled clinical trial in top athletes. The study will take place at the Australian Catholic University with principal investigator, Professor Louise Burke OAM PhD APD, Chair of Sports Nutrition at the Mary MacKillop Institute for Health Research. This follows the successful completion of a previous clinical trial that showed that Mitopure, a proprietary pure form of Urolithin A, boosts cellular function and improves leg muscle strength in 40+ year olds. This new clinical study aims to expand the clinical evidence of Mitopure in a younger and more athletic population.
Competition muscle fatigue is a well-known challenge for athletes and improving mitochondrial quality and density plays a direct role in optimizing cellular energy and muscle performance. Mitopure™ is the only clinically tested compound shown to increase muscle function by activating the selective recycling of damaged mitochondria, via a cellular renewal process known as mitophagy. There’s a growing interest among athletes for nutritional approaches to boost mitochondrial function. Scientific evidence combined with positive feedback from both amateur and professional athletes who have been taking Mitopure has served as a catalyst to expand into sports nutrition product applications. Professional basketball player Joel Embiid who has been taking Mitopure for several months is an advocate and comments “I’ve been working closely with Prof. Burke to take my health to the next level and Mitopure is now a core part of my daily regimen. I’ve never felt stronger.”
This clinical investigation brings the rigorous science of Mitopure to a population of athletes in the context of an intense training regimen. “Muscle fatigue, inflammation and faster recovery represent a big unmet need for elite athletes” says leading sports researcher and principal investigator of the study, Professor Louise Burke, OAM PhD APD. She continues, “Boosting cellular bioenergetics by accelerating the renewal of mitochondria is a novel approach to supporting peak performance in a very physically demanding population. We are really excited to investigate whether Mitopure can achieve these effects in highly trained athletes.”
Trained elite and sub-elite runners (n=36), aged between 18 and 40 years, participating in a sports training camp, will be enrolled in the double-blind, placebo-controlled, randomized trial. The study will evaluate the effects of Mitopure on muscle recovery, strength, endurance and running performance during a 3000-meter track race. More information can be found on clinicaltrials.gov under the identifier NCT04783207.
“We have shown that Mitopure can have a significant impact on the healthy aging population and are now expanding its application into the sports nutrition market where peak cellular health and muscle performance are essential. We’re excited to see how Mitopure can help athletes achieve their personal goals.” says Amazentis CEO and Co-Founder, Chris Rinsch, PhD.
